METHOD FOR FORMING RISK GROUP WITH CARCINOMA OF ESOPHAGUS

摘要

the invention u043eu0442u043du043eu0441u0438u0442u0441u00a0 to medicine, in particular u043au043eu043du043au043eu0438u043cu043cu0443u043du043eu043bu043eu0433u0438u0438. the purpose is to improve the effectiveness of u0438u0437u043eu0431u0440u0435u0442u0435u043du0438u00a0 u0432u044bu00a0u0432u043bu0435u043du0438u00a0 risk groups by u043eu043fu0440u0435u0434u0435u043bu0435u043du0438u00a0 in u0430u043du0442u0438u0433u0435u043du043du043eu043c composed of lymphocytes u043du0430u043bu0438u0447u0438u00a0 - a - b - 35 antigens. studied the distribution of n | and antigen in cancer of esophagus.the lymphocytes was assessed in the hla standard u043bu0438u043cu0444u043eu0442u043eu043au0441u0438u0447u0435u0441u043au043eu043c text panel ant sera directed to 23 of the antigens and lymphocytes u0434u043bu00a0 iss u043bu0435u0434u043eu0432u0430u043du0438u00a0 u0432u044bu0434u0435u043bu00a0u043bu0438 method u0446u0435u043du0442u0440u0438u0444u0443u0433u0438u0440u043eu0432u0430u043du0438u00a0 of u0434u0435u0444u0438u0431u0440u0438u0440u043eu0432u0430u043du043du043eu0439 blood in density gradient u0444u0438u043au043eu043bu043bu0430 - u0432u0435u0440u043eu0433u0440u0430u0444u0438 -. the composition of the b lymphocytes u0430u043du0442u0438u0433u0435u043du043du043eu043c 35 antigens is the basis u0434u043bu00a0 u0444u043eu0440u043cu0438u0440u043eu0432u0430u043du0438u00a0 risk groups. 3, table 2).